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Abstract
Background: Individuals of African descent living in western countries have increased rates of hypertension and
hypertension-related complications. Poor adherence to hypertension treatment (medication and lifestyle changes) has
been identified as one of the most important modifiable causes for the observed disparities in hypertension related
complications, with patient education being recommended to improve adherence. Despite evidence that culturally-
appropriate patient education may improve the overall quality of care for ethnic minority patients, few studies have
focused on how hypertensive individuals of African descent respond to this approach. This paper describes the design of
a study that compares the effectiveness of culturally-appropriate hypertension education with that of the standard
approach among Surinamese and Ghanaian hypertensive patients with an elevated blood pressure in Dutch primary care
practices.
Methods/Design: A cluster-randomized controlled trial will be conducted in four primary care practices in Amsterdam,
all offering hypertension care according to Dutch clinical guidelines. After randomization, patients in the usual care sites
(n = 2) will receive standard hypertension education. Patients in the intervention sites (n = 2) will receive three culturally-
appropriate hypertension education sessions, culturally-specific educational materials and targeted lifestyle support. The
primary outcome will be the proportion of patients with a reduction in systolic blood pressure  10 mmHg at eight
months after the start of the trial. The secondary outcomes will be the proportion of patients with self-reported
adherence to (i) medication and (ii) lifestyle recommendations at eight months after the start of the trial. The study will
enrol 148 patients (74 per condition, 37 per site). Eligibility criteria for patients of either sex will be: current diagnosis of
hypertension, self-identified Afro-Surinamese or Ghanaian,  20 years, and baseline blood pressure  140/90 mmHg.
Primary and secondary outcomes will be measured at baseline and at 3 1/2, 6 1/2, and eight months. Other measurements
will be performed at baseline and eight months.
Discussion: The findings will provide new knowledge on how to improve blood pressure control and patient adherence
in ethnic minority persons with a high risk of negative hypertension-related health outcomes.
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Background
Hypertension (HTN) is a major risk factor for cardiovas-
cular morbidity and mortality [1]. In western countries,
ethnic minority populations of African descent are dispro-
portionately affected by HTN and HTN-related cardiovas-
cular morbidity and mortality [2-4]. This has also been
observed among two major immigrant groups of African
descent in the Netherlands: African-Surinamese from the
former Dutch colony of Suriname (hereafter referred to as
Surinamese) [5], and Ghanaians [6,7]. Poor adherence to
prescribed medication and lifestyle changes such as
weight control, regular physical activity, avoidance of
tobacco, and a moderate intake of salt and alcohol, has
been identified as one of the most important modifiable
causes for the observed disparities in hypertension related
complications [8,9]. Enhancing patient adherence to such
therapeutic measures can be an important first step
towards eliminating disparities [4,6,9-11].
In the Netherlands, general practitioners (GPs) play an
important role in the treatment of HTN. European and
Dutch primary care guidelines recommend patient educa-
tion as a means of improving patients' motivation for and
ability to adhere to HTN treatment goals [12,13]. Medical
perceptions of disease and treatment can differ from lay
perceptions [14], and patients can have a major impact on
adherence to treatment [15-17]. HTN educators are there-
fore advised to employ "patient-centred" educational
approaches that allow them to explore individual
patients' beliefs and needs, and to find common ground
regarding treatment [18]. The Dutch guidelines recom-
mend focusing on the "5 As" (ask, assess, advise, assist
and arrange) [19]. Studies from the UK and the USA have
shown that patient beliefs about HTN and treatment can
differ between ethnic groups [20-24]. This was also a find-
ing from one of our previous studies, which focused on
White Dutch, Surinamese and Ghanaian hypertensive
patients living in the Netherlands [25]. Indeed, there is
increasing evidence, mainly from diabetes research, that
"culturally sensitive" patient education may have a posi-
tive influence on medication use and lifestyle changes
among ethnic minority patients [26,27]. Culturally-
appropriate patient education typically combines the
principle of "patient-centred" care with that of "culturally
competent" care [18]. To date, however, the European and
Dutch HTN guidelines for GPs have not provided any rec-
ommendations on how HTN educators might address cul-
tural variations in patients' perceptions of HTN.
Moreover, the literature offers few descriptions or evalua-
tions of means by which this might be achieved [11,28].
In a previous project, "Under Pressure 1", we developed a
multi-component provider intervention to facilitate cul-
turally-appropriate HTN education (CAHE) in Dutch pri-
mary care practices. This intervention mainly consisted of
a CAHE toolkit that could be used to supplement the
standard approach to HTN education recommended by
Dutch clinical guidelines [1]. To support HTN educators
using the toolkit, we developed an educational course and
a framework for feedback meetings. A pilot undertaken in
six primary care health centres (PCHC) in South East
Amsterdam demonstrated that healthcare providers who
had received the intervention thought it more important
to take a patient's cultural background into account when
delivering care. They also experienced fewer barriers to
delivering culturally-appropriate health education to
patients with cardiovascular problems than the control
group (Beune EJAJ, Haafkens JA, Mohrs J, Stronks K, Bin-
dels PJE: Pilot study evaluating the effects of an interven-
tion to enhance culturally appropriate hypertension
education among health care providers in a primary care
setting, submitted). In the pilot practices, general practice
assistants (GP assistants) and nurse practitioners (NP)
were responsible for conducting HTN education under
the supervision of GPs. A qualitative study of the experi-
ences of the professionals who had piloted the interven-
tion revealed a number of contextual barriers that had
hampered the implementation of the CAHE toolkit in
daily practice (Beune EJAJ, Haafkens JA, Bindels PJE: Pilot
study of barriers and enablers influencing the implemen-
tation of an intervention to stimulate culturally appropri-
ate hypertension education in a primary care setting,
submitted). Frequently-mentioned problems included
PCHCs being under-resourced, ongoing organizational
changes, limited access to office space, the rapid turnover
of GP assistants, and the fact that initially, GP assistants
lacked the skills to conduct patient-centred HTN. Fortu-
nately, many of these barriers could be addressed using
well-known strategies for supporting innovations in pri-
mary care [29-31]. We therefore concluded that it would
be feasible for Dutch primary care practices to adopt and
implement the intervention.
In this paper, we describe the design of and rationale for
our next project, "Under Pressure 2 (UP2)". The aim of
UP2 is to test, using a cluster-randomized trial, the effec-
tiveness of the previously-developed CAHE intervention
among hypertensive Surinamese and Ghanaian patients.
The latter should be receiving care in a Dutch primary care
setting, and should have an elevated blood pressure (that
is, greater than or equal to 140/90 mmHg). Our primary
hypothesis is that a higher proportion of patients rand-
omized to the CAHE intervention will have a reduction in
systolic blood pressure (SBP) greater than or equal to 10
mmHg at eight months after the start of the intervention,
as compared to those randomized to the usual care condi-
tion. Our secondary hypotheses are that a higher propor-
tion of patients randomized to the intervention will be
adherent to the prescribed (i) medication and (ii) lifestyle
recommendations at eight months after the start of theBMC Health Services Research 2009, 9:193 http://www.biomedcentral.com/1472-6963/9/193
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intervention, as compared to those randomized to the
usual care condition.
Methods
Study design
The study will consist of a cluster-randomized controlled
trial with two conditions: an intervention condition (IC)
and a usual care condition (UC), as shown in Figure 1.
Using a balanced design, four PCHCs will be randomly
assigned to the IC (n = 2) or the UC (n = 2). Prior to ran-
domization, the PCHCs will be matched on the size of the
practices. A member of the Academic Medical Center's
(AMC) Data Management Services team will carry out the
randomization of the practices, and this team member
will be blinded for the practices' identities. In those
PCHCs assigned to the UC, the patients studied will
receive the standard HTN education, based on the recom-
mendations in the Dutch clinical guidelines [1]. In the
PCHCs assigned to the IC, meanwhile, the patients stud-
ied will receive three CAHE sessions at two weeks post
baseline, and three and six months thereafter. Data will be
collected at baseline, during two office visits three-and-a-
half and six-and-a-half months thereafter, and at eight
months past baseline. The primary and secondary out-
comes will be calculated based on data collected at base-
line and eight months thereafter.
Study sites
South East Amsterdam is one of the areas in the Nether-
lands that has a relatively high percentage of Surinamese
and Ghanaian inhabitants. We have already selected four
PCHCs in South East Amsterdam for the study. The inclu-
sion criteria for each of the sites are that they (i) provide
HTN care according to a practice protocol based on the
Dutch clinical guidelines [1], and (ii) are not participating
in similar studies to improve cardiovascular risk manage-
ment.
Study population
To be recruited for the study, patients have to fulfil the fol-
lowing eligibility criteria: (i) self-identified as Surinamese
or Ghanaian; (ii) aged 20 or over; (iii) diagnosis of HTN
with the International Classification of Primary care ICPC
codes K85, K86 or K87; and (iv) an uncontrolled BP at the
last office visit. Following the Dutch clinical guidelines, an
elevated BP is defined as SBP/diastolic blood pressure
(DBP)  140/90 mmHg. In addition, all patients must
have an elevated BP at the baseline assessment meeting.
Patients will be excluded if they have type 1 or type 2 dia-
betes, on the grounds that many diabetes patients with
HTN may already be following diabetes education pro-
grammes that share characteristics with the intervention
that will be offered in this trial. Patients will also be
excluded if they are participating in other cardiovascular
disease-related trials, if the GP who is treating them judges
them to be unfit for participation (e.g. due to co-morbid-
ity), or if they are unable or unwilling to provide informed
consent.
Sample size calculation
Our power analysis for sample size is based on the pri-
mary outcome measure of the study: SBP at baseline
minus SBP at eight months after baseline. SBP has been
selected because it is the most important factor for deter-
mining a patient's cardiovascular risk profile [1]. Further-
more, in almost all cases, the DBP will become lower if the
SBP becomes lower. Following the literature, we consider
a reduction of the SBP of 10 mmHg to be a clinically rele-
vant difference [16,32].
The following rationale was used for the power calcula-
tion of the sample. The trial will be conducted in four
PCHCs. We assume that patients in the IC and the UC will
have similar demographic characteristics and that they
will have been treated similarly, in line with the Dutch
clinical guidelines [1]. We therefore expect there to be no
differences between the four PCHCs with respect to the
mean BP of patients with HTN. We can assume that the
inter-cluster correlation is low (3%), because this is a ratio
of the between-cluster and the low intra-cluster variance.
In order to demonstrate a statistical difference of 10
mmHg with a standard deviation (SD) of 15 and a two-
sided alpha of 5% and a power of 80%, we need a sample
size of 148 patients (74 per treatment condition and 37
per PCHC). As we expect a drop-out rate of 40% prior to
inclusion, we aim to recruit 246 patients.
Registry data from the four PCHCs that have been
included in the study show that each PCHC has about 100
Surinamese and 38 Ghanaian registered patients who are
being treated for HTN (K85,86, K87). Based on data from
Agyemang et al. [5], it is estimated that about 63% of
these patients will have a blood pressure > 140/90 mmHg.
We therefore expect that we will be able to obtain an ade-
quate sample size for this study.
Approvals and data and safety monitoring
The study has been approved by the AMC's Medical Ethics
Committee, which forms part of the University of Amster-
dam in the Netherlands (protocol ID MEC09/070). Par-
ticipants will provide written informed consent prior to
enrolment. Recruitment procedures will be conducted in
accordance with the Dutch Medical Research Involving
Human Subjects Act and the World Medical Association
Declaration of Helsinki.
Patient recruitment
The following steps will be taken in order to recruit
patients. First, the electronic medical records (EMR) from
the four selected PCHCs will be reviewed in order to selectBMC Health Services Research 2009, 9:193 http://www.biomedcentral.com/1472-6963/9/193
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Study design Figure 1
Study design.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Usual Care 
 
Patients receive: HTN care and 
education as usual. 
 
Physicians and HTN educators are 
encouraged to follow the Dutch HTN 
guidelines. 
 
- Outcomes Assessment (8 months) 
Primary outcome: proportion of patients with a significant reduction in the SBP (baseline SBP 
minus SBP at 8 months, i.e. > 10 mmHg). 
 
Secondary outcomes: proportion of patients with adequate self-reported adherence to (i) 
prescribed medication and (ii) lifestyle changes, as measured by the Morisky scale. 
 
Two office 
visits for 
assessment of 
BP and 
adherence to 
prescribed 
medication/ 
lifestyle at 
3½ and 6½ 
months after 
baseline. 
Intervention 
 
Patients receive: HTN care as usual from 
physician; 3 culturally-appropriate 
educational sessions on HTN and HTN 
management (2 wks, 3½ and 6½ months 
past baseline), culturally-adapted 
education materials, referrals to facilities 
that support therapeutic lifestyle changes 
from HTN educator. 
 
Physicians are encouraged to follow 
Dutch HTN guideline. HTN educator 
receives training in culturally-
appropriate HTN education.  
2 Usual Care Sites  2 Intervention Sites 
Randomization and baseline assessment 
 
-  Select 4 primary care health centres randomized to Intervention or Usual Care 
Conditions (inclusion criteria size, use of Dutch College of GPs’ HTN 
guidelines) 
-  Enrol 148 patients (74 per condition, 37 per site). Inclusion criteria: self-
identified as Surinamese or Ghanaian, either sex, 20 years or older, diagnosed 
with HTN, uncontrolled HTN (> 140/90 mmHg) at the last office visit. 
-  Collect baseline data primary outcome (BP measurement), secondary 
outcomes (self-reported adherence to prescribed medication and lifestyle 
changes) and additional background factors. 
- Collect data primary outcome (BP measurement), secondary outcomes (self-reported 
adherence to prescribed medication and lifestyle changes) and additional background factors at 
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all patients who meet the inclusion criteria for HTN, age
and sex. As Dutch EMRs provide no information on
patient ethnicity, attending physicians will help to iden-
tify Ghanaian and Surinamese patients according to their
knowledge of the patients or their names. The relevant
patients' GPs will be informed of their potential eligibil-
ity, and the GPs will be asked for their permission to enrol
the patients in the study. Eligible patients will receive a let-
ter from the researchers by post, which will have been co-
signed by their GP. This letter, which will be written in
Dutch (Surinamese patients) or English (Ghanaian
patients), will inform patients about the study and invite
them to participate. It will include a pre-paid postcard that
can be sent back to the research staff if the patient con-
cerned wishes to participate in the study. If a patient fails
to react, a member of the research team will call him or
her to offer more information about the study and discuss
participation.
If a patient expresses interest in participating, a staff mem-
ber will check whether they meet the eligibility criteria,
and will ask whether they are willing to sign an informed
consent form. Eligible patients who agree to sign this form
will be invited to attend a one-hour baseline assessment
meeting. After making sure that the patient has signed the
consent form, a research assistant (RA) will use this meet-
ing to assess a patient's SBP and DBP, height, weight, and
BMI, using standardized techniques (see below), and to
obtain self-reporting measures using the baseline ques-
tionnaire. Patients who do not meet the inclusion criteria
for BP or ethnicity will not be included in the study. These
patients will instead receive the standard five minutes of
coaching about HTN care from the RA who conducts the
baseline measurement. Patients from IC practices will be
assigned to the IC condition, while those from UC prac-
tices will be assigned to the UC condition. The RA, who
will be blinded for the IC of the patient's PCHC, will refer
all eligible patients to their PCHC's GP assistant. The GP
assistant will then provide patients with a letter outlining
further steps in the study. They will also make appoint-
ments with patients for follow-up office visits, in line with
instructions received from the research staff. To encourage
participation, all patients who are included in the study
will be promised a small reward or present (value of 25
euros) after they have completed the final assessments,
regardless of the intervention site.
Interventions
Intervention condition (IC)
Patients in the IC practices will receive HTN care as recom-
mended in the Dutch clinical guidelines. Instead of the
standard counselling to facilitate adherence to medication
and therapeutic lifestyle changes, patients will receive: (i)
three culturally-appropriate HTN education (CAHE) ses-
sions over a period of six and a half months, conducted by
a trained NP; (ii) culturally-specific, educational written
material; and (iii) if necessary, referrals to neighbourhood
facilities that may help Surinamese and Ghanaian patients
to adopt healthier lifestyles. Moreover, (iv) prior to the
second and third counselling session, an assessment of
each patient's BP and self-reported medication and life-
style adherence will be made using standardized meas-
ures. These measures are described below.
Culturally-appropriate HTN education (CAHE)
The first session will take place two weeks after the base-
line assessment interview, and the next two sessions will
occur three and six months thereafter. The Dutch clinical
guidelines recommend the 5 As [19] as the preferred strat-
egy for supporting patients in achieving treatment goals,
such as adherence to prescribed medication, dietary
changes, weight loss, reduced sodium intake, increased
physical activity and moderate use of alcohol [1]. While
CAHE also uses this framework, it has the additional aim
of eliciting and discussing culturally-specific aspects of
patients' perceptions of HTN and HTN treatment. This
method is based on the work of Arthur Kleinman [33], as
well as more recent approaches to improving adherence in
patients with HTN [34] that were further adapted and
piloted in our previous study. In short, after identifying
potential communication barriers and establishing a rap-
port with the patient, the first session will focus on the
patient's beliefs about HTN. The next two sessions will
deal with the daily challenges presented by achieving
HTN treatment goals within the broader context of the
patient's life (see Additional file 1 and 2).
Provision of information
Patients will also be given information leaflets that pro-
vide answers to frequently-asked questions about HTN.
These will be designed to address the specific languages,
customs, habits, norms and dietary cultures that charac-
terize the Surinamese and Ghanaian communities.
Supporting healthier lifestyles
If necessary, patients will be referred to neighbourhood
facilities offering healthier lifestyle support that is tailored
to Surinamese and Ghanaian patients, based on a referral
list that will be established for this purpose.
The counsellor
In order to ensure treatment fidelity and to avoid previ-
ously identified organizational- and healthcare-related
obstacles to implementation, we will appoint one NP
who will provide CAHE to all IC patients. The NP will
have extensive training and experience in using the coun-
selling approach recommended in the Dutch clinical
guidelines (the 5 As). Prior to the intervention, she will
receive additional training in order to improve her knowl-
edge of HTN in the Ghanaian and Surinamese communi-BMC Health Services Research 2009, 9:193 http://www.biomedcentral.com/1472-6963/9/193
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ties, general cross-cultural counselling techniques, and the
specific CAHE method that will be used in this study. The
training manual and methods that were developed during
our previous study will be used for this purpose. During
the trial, the NP will also be offered an opportunity to
receive feedback from a member of the research team.
UC condition
Patients in UC sites will receive standard HTN care and
education, following the recommendations in the Dutch
clinical guidelines [1]. After completing the baseline
assessment, each patient will be given appointments for
two office visits at three-and-a-half and six-and-a-half
months thereafter for the assessment of their BP and self-
reported adherence to medication and lifestyle changes.
Regardless of the randomization condition, it will be pos-
sible to charge all office visits carried out in the context of
this trial to health insurance companies.
Outcomes, measures and data analysis
Primary outcome
The primary outcome measure is the proportion of
patients with a significant reduction in the SBP (10
mmHg; SD = 15) at eight months after inclusion.
Secondary outcomes
The secondary outcome measures are: (i) the proportion
of patients with adequate adherence to prescribed medica-
tion at eight months after inclusion; and (ii) the propor-
tion of patients with adequate adherence to lifestyle
recommendations at eight months after inclusion.
Data will also be collected with respect to factors that
characterize the patient group (baseline demographics,
baseline medical chart data) and a number of factors that
may influence patients' HTN management (perceptions
of HTN, perceptions of medications, self-efficacy, experi-
ence of social support in HTN management, and level of
satisfaction with care). In addition, data relating to the
process of implementing the intervention will be col-
lected.
Measures
The measurements to be studied can be divided into five
categories: (1) physiological measures, (2) self-reporting
measures, (3) pharmacy data, (4) chart data and (5) proc-
ess data. Table 1 summarizes the measures according to
the timeline. A trained RA will conduct all physiological
and self-reporting measures at baseline and at eight
months. Attending NPs at the IC and UC practices will
take a subsection of these measures (BP and self-reported
adherence to medication and life style changes) at three-
Table 1: Measures used in the trial and timeline
Measures Baseline 2
wks
3 1/2
mnths
6 1/2
mnths
8
mnths
9
mnths
Physiological measures
- Office BP measurements X X X X
- Height, weight, BMI X X
- Hip and waist size X X
Self-reporting measures
- Patient demographics X
- Additional cardiovascular risk factors (physical activity, smoking, alcohol, sodium intake) X X
- Medication adherence X X X X
- Adherence to lifestyle recommendations X X X X
- Perceptions of HTN X X
- Perceptions of medication X X
- Self efficacy XX
- Experience of social support in HTN management X X
- Satisfaction with care X X
- Discrimination XX
- Perceived stress X X
Pharmacy data
- Refill dates XX X X
Chart data
- Prescribed medication X
- Prescribed lifestyle measures X
- Co-morbidity X
Process data
- Registration office visits, patient drop-out X X X X X
- Patients interviews XBMC Health Services Research 2009, 9:193 http://www.biomedcentral.com/1472-6963/9/193
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and-a-half and at six-and-a-half months. A member of the
research staff will collect pharmacy and chart data. Time
registration and patient drop-out data for the process
analysis will be collected using registrations made by the
RA and the NPs. A member of the research staff will con-
duct post-intervention interviews with patients.
Physiological measures
BP will be measured three times using an automated BP
monitor (Omron 705-IT), with the patient seated com-
fortably for five minutes. The average of the last two read-
ings will be used as a measure for each visit. The same
procedure will be used by trained NPs during office visits
at three-and-a-half and six-and-a-half months after base-
line.
Height and weight will be measured in the absence of
shoes and heavy clothing, using a tape rule and a vali-
dated scale respectively. All measurements will be
recorded to the nearest 0.1 cm and 0.1 kg. These measures
will be used to compute a patient's BMI. Waist size will be
measured by putting the tape horizontally around the
smallest part of the waist. Hip size will be measured by
putting the tape horizontally around the widest part of the
hips.
Self-reporting measures
In order to collect socio-demographic data describing the
study population, we have adapted an instrument used in
an earlier study [35]. The variables will include age, gen-
der, self-identified ethnicity, educational level, employ-
ment status, household income, marital status, household
composition, duration of stay in the Netherlands, dura-
tion of HTN, and health insurance status.
To establish the presence of additional cardiovascular risk
factors, we will use an instrument that contains six ques-
tions relating to physical activity, smoking, alcohol and
sodium intake. Questions will be based on an instrument
used in a previous study [35].
Adherence to prescribed antihypertensive medication will
be measured with the widely-used four-item scale devel-
oped by Morisky [36]. This instrument has been well val-
idated in studies of African American inner-city
populations [37-39]. The scale asks patients to respond
with "yes" or "no" to a set of four questions. A positive
response to any question indicates a problem with adher-
ence. Each positive answer is assigned a score of 1. The
total possible score is 4, with a higher score indicating a
poorer level of adherence. In this study, patients with a
score of  1 will be categorized as non-adherent. In addi-
tion, six items will be used that are based on our previous
study [40].
To assess adherence to lifestyle recommendations, we will
use four items derived from the Morisky scale [36]
adapted for the purpose of this study.
Perceptions of HTN and HTN treatment will be measured
using 52 items: of these, nine will be from the IPQ-brief
[41], 18 will be from the IPQ-R HTN [42], five will be
derived from our earlier studies on perceptions of HTN
and HTN management among Surinamese and Ghana-
ians [40,43,44], and 20 items will be adapted from the
IPQ-R [45]. The validity and the reliability of the IPQ-brief
and the IPQ-R are well established [41,45,46]. Patients'
perceptions of antihypertensive medications will be meas-
ured using the ten-item BMQ [47], an instrument that has
good internal consistency and validity [48,49]. In addi-
tion to this, we will add three items that are based on our
previous study [40].
To measure patients' self-efficacy in HTN management,
the 13-item MASES-R will be used. This instrument has
good internal consistency and predictive and convergent
validity [50].
Social support will be measured using the 12-item
DUSOCS [51], which, as demonstrated by previous stud-
ies, has good validity and reliability [37].
Satisfaction with care will be measured using six items of
the Consumer Quality Index-diabetes [52]. Similar Con-
sumer Quality Index instruments have demonstrated
good construct and discriminating validity and internal
consistency in previous Dutch studies [53,54]. In addi-
tion, five items from the Quote-Migrant will be used,
which has been specifically developed to measure the
experienced quality of care in migrant populations [55].
Socio-demographic data will only be measured at base-
line. Most of the other self-reporting measures will be col-
lected at baseline and at eight months thereafter.
The Morisky scale will also be used to assess adherence to
medication and lifestyle recommendations during the sec-
ond and third office visits, respectively three-and-a-half
and six-and-a-half months after the baseline assessment.
Patients will be asked to complete these questionnaires in
practice waiting rooms, prior to meeting the NP.
Discrimination and stress will be measured with two
scales from the CAATCH trial [56].
Pharmacy data
In addition to self-reporting data, pharmacy data will be
used to check self-reported adherence to medication.
These data will allow us to measure refill adherence; that
is, the interval between the day when a prescription ends,BMC Health Services Research 2009, 9:193 http://www.biomedcentral.com/1472-6963/9/193
Page 8 of 11
(page number not for citation purposes)
and the day on which a new prescription is refilled [57]. A
patient is defined as adherent if the prescription is refilled
within seven days of the designated refill date. This
method has also been used in other studies [58].
Chart data
In addition to self-reported biographical and disease data,
relevant chart data from the patients' charts will be
extracted from the EMR as soon as patients have been
included in the study. The following data will be
extracted: SBP and DBP measured during the last two
office visits; prescribed medication; the presence of addi-
tional risk factors for cardiovascular disease (physical
exercise, diet, sodium, smoking, alcohol, height, weight,
BMI, waist and hip circumference, glucose, cholesterol);
and the presence of previous cardiovascular diseases
(myocardial infarction, decompenstatio cordis, TIA,
CVA), kidney insufficiency, liver disease, dementia or
mental health problems. In a previous study, we found
that GP registration data can sometimes be incomplete
[40]. If these data are indeed sufficient, they will be used
as additional information to describe the background
characteristics of the study population, and to control for
confounders.
Process data
Time registrations for office visits and additional activities
made by the RA and NPs will be used to make a cost anal-
ysis of the intervention. Registration data on patient drop-
out will be used to analyse the feasibility of undertaking
the intervention for the patients groups in question.
Moreover, qualitative interviews with patients in the IC
and the UC conditions are planned to explore patients'
experiences of barriers to and incentives for participating
in the study. We will also enquire about non-reimbursa-
ble expenses that might arise from participating in the
study, such as travel costs and costs related to lifestyle
changes.
Blinding
Due to the nature of the interventions concerned, com-
plete blinding of investigators and professionals working
in the PCHCs would be impossible. However, the RA who
will conduct the assessments at baseline and at eight
months will be masked for the IC of the PCHCs. All BP
measurements will be taken with a standard automated
measurement device that can prevent ascertainment bias.
Even though physicians may be aware of the IC of their
healthcare centre, we consider contamination to be
unlikely on the grounds that the intervention (CAHE) will
require the use of specific expertise and tools. Finally, data
managers will be strictly blinded for the IC. All prelimi-
nary data will be stored in one dataset until the end of the
intervention.
Planned data analysis
All imported data will be controlled at random for mis-
codings. As a first step, univariate analyses will be per-
formed to compare the distribution of variables and to
identify abnormalities.
Primary and secondary outcomes will be calculated
according to the "intention to treat" principle. The pri-
mary outcome measure, which will be calculated for every
patient, will be the observed baseline SBP minus the SBP
at eight months. Subsequently, the mean within group
difference will be calculated separately for patients in the
IC and UC conditions. Finally, the difference between
these within group differences will be calculated with the
accompanying SD. As stated previously, we regard a
reduction of the SBP of 10 mmHg with a SD of 15 and a
two-sided alpha of 5% in the IC group (as compared to
the UC group) as a clinically relevant difference.
The secondary outcomes will be calculated using the
dichotomous outcomes of measurements on the Morisky
scale with respect to adherence to prescribed medication
and lifestyle changes. The analytical procedure will be
similar to that described for the primary outcome meas-
ure.
In a further analysis of the primary and secondary out-
comes, we will use univariate and multi-level analyses
that will include other data that may potentially affect the
outcomes. If the N is sufficient, we will perform separate
subgroup analyses for gender and ethnicity. A p of 0.05
will be used as the critical value for all analyses. For sub-
group analyses, the p value will be corrected according to
the number of analyses conducted.
Discussion
In western countries, there is an urgent need to improve
BP control among hypertensive patients of African
descent. In the US, trials of interventions to enhance BP
control and patient adherence to prescribed medications
and lifestyle changes have focused on African American
patients. Two of these trials are currently taking place
[11,56] and one recently finished [37]. To our knowledge,
the present study is one of the first European trials to
address this issue. The US trials are evaluating the effect of
interventions that are based on the principle of motiva-
tional interviewing [59]. The specific contribution of the
present study is that the intervention builds on the princi-
ples of "culturally-appropriate counselling" [60], which
can be used to supplement motivational interviewing.
Another key characteristic of the intervention is that it has
been developed and piloted using data from patients' own
perceptions of HTN [40,43,44]. Moreover, drawing on
theories of effective quality improvement in primary careBMC Health Services Research 2009, 9:193 http://www.biomedcentral.com/1472-6963/9/193
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[30,31], the feasibility for implementation by care provid-
ers has already been established in a previous pilot study.
If the results are positive, we hope that this intervention
will find wider application, so that it may contribute to
efforts to reduce ethnic disparities in HTN outcomes.
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